In adult patients with type 1 or type 2 diabetes who are non‑smokers, have FEV1 ≥ 80 % predicted, and no chronic lung disease, how should inhaled rapid‑acting insulin (Afrezza) be initiated, dosed, monitored, and what are its contraindications?

Inhaled Insulin (Afrezza) in Adult Diabetes: Initiation, Dosing, and Monitoring

Inhaled insulin (Afrezza) is a rapid-acting prandial insulin option for adult non-smokers with type 1 or type 2 diabetes who have normal lung function (FEV1 ≥80% predicted), offering an alternative to injectable rapid-acting analogs with comparable glycemic control but requires mandatory pulmonary function monitoring. 1, 2

Patient Selection and Contraindications

Absolute Contraindications

• Chronic lung disease including asthma or COPD 2
• Active smoking or recent smoking cessation 2
• Episodes of hypoglycemia 2
• Hypersensitivity to regular human insulin or excipients 2

Relative Contraindications (Risk-Benefit Assessment Required)

• Active lung cancer, prior history of lung cancer, or high risk for lung cancer 2
• Diabetic ketoacidosis risk - not recommended for DKA treatment 2

Pre-Initiation Requirements

Perform detailed medical history, physical examination, and baseline spirometry (FEV1) in ALL patients before starting Afrezza 2. This is mandatory per FDA labeling to identify potential lung disease.

Initiation and Dosing

Starting Doses

For insulin-naïve patients or those switching from subcutaneous rapid-acting analogs:

• Initial Afrezza dose should be approximately 2 times the subcutaneous rapid-acting analog dose based on bioequivalence 3, 4
• Administer at the beginning of each meal 2
• Available cartridge strengths: 4 units, 8 units, or 12 units 2

Practical dosing approach for type 2 diabetes:

• Mean effective prandial doses in clinical trials were 18-19 units per meal 5
• Rapidly titrate based on postprandial blood glucose using a treatment algorithm 5

For type 1 diabetes:

• Use as part of multiple daily injection regimen with basal insulin (insulin degludec or other long-acting analog) 1, 3
• The 2025 ADA Standards explicitly list prandial insulin options as injectable rapid/ultra-rapid-acting analogs, injectable short-acting human insulin, or inhaled human insulin 1

Dose Adjustments

• Increase by 1-2 units or 10-15% if A1C above goal 1
• For hypoglycemia without clear cause, lower corresponding dose by 10-20% 1
• If blood glucose control not achieved despite high Afrezza doses, consider discontinuing 2

Monitoring Requirements

Pulmonary Function Monitoring (Critical)

Assess spirometry (FEV1): 2

• Before initiating therapy (baseline)
• After 6 months of therapy
• Annually thereafter, even without pulmonary symptoms

If FEV1 declines ≥20% from baseline, consider discontinuing Afrezza 2. Note that slight reversible declines in pulmonary function are expected with treatment 6.

Glycemic Monitoring

• Increase frequency of blood glucose monitoring during initiation and dose adjustments 2
• For patients at higher risk for hypoglycemia or with reduced symptomatic awareness, increase monitoring frequency 2
• In patients at risk for DKA, increase glucose monitoring frequency and consider alternate insulin delivery route 2

Additional Monitoring

• Potassium levels in patients at risk of hypokalemia 2
• Signs and symptoms of heart failure if used with thiazolidinediones 2
• Reevaluate insulin treatment plan every 3-6 months 1

Expected Outcomes and Efficacy

Glycemic Control

• HbA1c reduction of approximately 1.6% in type 2 diabetes (from 9.0% to 7.4% over 12 weeks) 5
• HbA1c reduction of 0.23-0.36% in type 1 diabetes when switching from MDI/SAP 3
• Time in range (70-180 mg/dL) increased from 42% to 66% in type 2 diabetes 5
• Daytime time in range increased by 5.1% overall in type 1 diabetes, with 8.6% improvement in MDI/SAP users 3

Hypoglycemia Profile

• Significantly less hypoglycemia compared to injectable rapid-acting analogs in type 1 diabetes 4, 7
• Time <54 mg/dL remained low (0.5% baseline to 0.7% at 13 weeks) 3
• Time below range increased modestly from 1.1% to 2.6% in type 2 diabetes 5

Weight Effects

• Less weight gain compared to subcutaneous insulin aspart 7

Common Adverse Events and Management

Respiratory Symptoms

• Cough is the most common non-hypoglycemia adverse event (28% vs 5.2% with comparators) 6, 7
• Cough is generally mild, dry, and decreases over time 6, 7
• Throat pain or irritation occurs in ≥2% of patients 2, 6

Serious Pulmonary Concerns

• Acute bronchospasm can occur - this is the basis for the boxed warning 2
• Two lung malignancies reported in patients with smoking history during clinical trials 6

Special Considerations

Switching from Automated Insulin Delivery (AID)

• Overnight time in range decreased by 15.6% when AID users switched to Afrezza-degludec 3
• Daytime control remained comparable 3
• This represents a significant trade-off that patients should understand before switching.

Patient Acceptance

• Only 40% of participants desired to continue Afrezza after 13 weeks in one study 3
• Positive patient-reported outcomes noted in other trials 7

Combination Therapy

• Can be used with basal insulin (degludec, glargine, etc.) 1, 3
• May be combined with GLP-1 receptor agonists or SGLT2 inhibitors per standard diabetes management 1
• Exercise caution with thiazolidinediones due to fluid retention risk 2

Clinical Pitfalls to Avoid

1. Failing to perform baseline spirometry - this is mandatory and non-negotiable 2
2. Using 1:1 dose conversion from subcutaneous insulin - Afrezza requires approximately 2x the dose due to bioequivalence differences 3, 4
3. Prescribing to smokers or patients with any chronic lung disease - this is absolutely contraindicated 2
4. Neglecting annual pulmonary function testing - required even without symptoms 2
5. Using for DKA treatment - not appropriate for this indication 2